Idera Pharmaceuticals, Inc. (IDRA)

$0.438

-0.02 (-4.58%)
Rating:
Recommendation:
Buy
Symbol IDRA
Price $0.438
Beta 1.492
Volume Avg. 1.10M
Market Cap 23.199M
Shares () -
52 Week Range 0.3-1.17
1y Target Est -
DCF Unlevered IDRA DCF ->
DCF Levered IDRA LDCF ->
ROE -69.27% Strong Sell
ROA -72.43% Strong Sell
Operating Margin -
Debt / Equity 16.60% Neutral
P/E -
P/B 0.90 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IDRA news


Mr. Vincent Milano
Healthcare
Biotechnology
NASDAQ Capital Market

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.